Orum Ascending High Mountain Of Undruggable RAS Protein

Emerging Company Profile: Orum Therapeutics is aiming to develop a first-in-class therapeutic antibody for cancer and other intractable diseases, using its unique cell-penetrating antibody platform. Following a successful Series A financing, the young South Korean biotech’s next big milestone is to enter clinical trials by 2019 with its first program in oncology, targeting activated RAS protein.